Overview

* DRI Healthcare Q2 total income at $44.1 mln, compared with 41.6 mln year ago

* Co internalized investment management, aligning management with unitholders

* Repurchased ~958K units for $9.1 mln under NCIB

Result Drivers

* INTERNALIZATION - DRI Healthcare completed the internalization of its investment management function, aligning management with unitholders

* EKTERLY INVESTMENT - Increased royalty entitlement on Ekterly by making a $22 mln optional payment, enhancing future cash flows

* UNIT REPURCHASE - Repurchased ~958K units for $9.1 mln under NCIB, enhancing shareholder value

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Total $44.13

Income mln

Q2 $0.51

Adjusted

Cash

Earnings

per Unit

Q2 Net $0.01

Earnings

per Unit

Q2 Net $376,000

Income

Q2 $30.37

Adjusted mln

EBITDA

Q2 76.0%

Adjusted

EBITDA

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Dri Healthcare Trust is C$19.25, about 22.3% above its August 13 closing price of C$14.95

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)